ArticleTranslational lung cancer research2021

Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.